Evidence of strong expression of CD30 on TAMs in MF and SS patients suggests that depletion of macrophages is one of the possible targets of the anti-CD30 monoclonal antibody Brentuximab vedotin [189]. The gene discussed is TNFRSF8; the disease is synovial sarcoma.